Jeff Meacham

“I also wanted to say congrats on the quarter. I had two related ones on Reddit TruTide. The first one is, do you need a commercial strategy to protect against whatever it is that's apparently available today, or will that solve itself, you know, with formal approval?”

“I had a bigger picture one for Dan or perhaps Andy. When you look at Gilead's core therapeutic areas, you guys have clearly diversified the business today in terms of pipeline, but you're not really there yet with respect to sales.”

“What are you guys ultimately looking for in the combo studies? Is it quarterly dosing? Is it indications outside of diabetes? Is it rid of trutide-like efficacy?”

“The first one in CF, on A28 or the other assets in phase one, what are some of the clinical attributes you're looking for? I wasn't sure if you're looking for perhaps a nominally better treatment effect or if there is a potential to not need liver monitoring, for example, in future combos.”

“Chris or Christian, I guess I just wanted to talk about the adept and milvexian studies going into 2027. I know they're event-driven, but maybe can you talk a little bit about, you know, what this means relative to your initial assumptions?”